X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES MERCK LTD VENUS REMEDIES/
MERCK LTD
 
P/E (TTM) x -817.3 26.3 - View Chart
P/BV x 0.2 2.9 8.1% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 VENUS REMEDIES   MERCK LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
MERCK LTD
Dec-16
VENUS REMEDIES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2181,060 20.6%   
Low Rs82623 13.2%   
Sales per share (Unadj.) Rs365.6632.4 57.8%  
Earnings per share (Unadj.) Rs1.545.7 3.3%  
Cash flow per share (Unadj.) Rs37.962.3 60.9%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs382.5388.8 98.4%  
Shares outstanding (eoy) m11.4416.60 68.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.3 30.8%   
Avg P/E ratio x101.018.4 548.6%  
P/CF ratio (eoy) x4.013.5 29.3%  
Price / Book Value ratio x0.42.2 18.1%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m1,71713,969 12.3%   
No. of employees `0001.01.6 64.4%   
Total wages/salary Rs m3241,487 21.8%   
Avg. sales/employee Rs Th4,100.76,631.9 61.8%   
Avg. wages/employee Rs Th318.0939.2 33.9%   
Avg. net profit/employee Rs Th16.7479.4 3.5%   
INCOME DATA
Net Sales Rs m4,18310,498 39.8%  
Other income Rs m20242 8.3%   
Total revenues Rs m4,20310,741 39.1%   
Gross profit Rs m8121,135 71.5%  
Depreciation Rs m417276 151.3%   
Interest Rs m3800-   
Profit before tax Rs m351,102 3.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18343 5.3%   
Profit after tax Rs m17759 2.2%  
Gross profit margin %19.410.8 179.4%  
Effective tax rate %51.631.1 165.6%   
Net profit margin %0.47.2 5.6%  
BALANCE SHEET DATA
Current assets Rs m2,7716,410 43.2%   
Current liabilities Rs m1,9318,828 21.9%   
Net working cap to sales %20.1-23.0 -87.1%  
Current ratio x1.40.7 197.6%  
Inventory Days Days12558 216.8%  
Debtors Days Days5438 140.0%  
Net fixed assets Rs m5,3281,406 378.9%   
Share capital Rs m114166 68.9%   
"Free" reserves Rs m4,1776,286 66.5%   
Net worth Rs m4,3766,455 67.8%   
Long term debt Rs m1,9110-   
Total assets Rs m8,4288,828 95.5%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.2 41.7%   
Return on assets %4.78.6 54.8%  
Return on equity %0.411.8 3.3%  
Return on capital %6.617.1 38.6%  
Exports to sales %08.3 0.0%   
Imports to sales %20.521.0 97.5%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs m8582,209 38.9%   
Fx inflow Rs m0959 0.0%   
Fx outflow Rs m8582,612 32.9%   
Net fx Rs m-858-1,653 51.9%   
CASH FLOW
From Operations Rs m4691,070 43.8%  
From Investments Rs m29-750 -3.9%  
From Financial Activity Rs m-464-150 309.4%  
Net Cashflow Rs m35171 20.2%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.2 18.2 1.0%  
FIIs % 0.6 1.0 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 29.1 228.2%  
Shareholders   20,121 28,591 70.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ORCHID PHARMA LTD  STERLING BIOTECH  TORRENT PHARMA  UNICHEM LAB  CIPLA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 18, 2017 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS